S*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award
March 05 2009 - 5:00PM
PR Newswire (US)
SINGAPORE, March 6 /PRNewswire/ -- S*BIO Pte Ltd today announced
that it has received the BioSpectrum Editor's Choice, Emerging
BioScience Company of Singapore Award. Dr. Stephen Rhind, Senior
Vice President Corporate Development, S*BIO, received the award on
behalf of the company, from Mr. S. Iswaran, Singapore's Senior
Minister for Trade and Industry. The Annual BioSpectrum awards
recognize outstanding contributions to the growth of the
biotechnology and life sciences industry in Asia. S*BIO was chosen
for its innovative business model and leading position in
Singapore's biotechnology industry. "We are proud to be named
Singapore's emerging bioscience company of the year," said Dr.
Jan-Anders Karlsson, CEO of S*BIO. "Receiving this award not only
reflects S*BIO's leading role in oncology drug discovery and
development but also demonstrates the commitment of Singapore's
government to the local biomedical sciences industry. "We thank
everyone at S*BIO whose combined efforts led to the significant
progress we made in moving our leading candidates, the JAK2
inhibitors SB1518 and SB1578, the HDAC inhibitor SB939, and the
multi-kinase inhibitor SB1317, through pre-clinical and clinical
development." About BioSpectrum Launched in 2003 by Asia's leading
specialty publishing company, CyberMedia India Ltd., BioSpectrum is
India's and Asia-Pacific's most widely circulated and read Life
Sciences media platform. It comes out in two monthly editions:
India edition published from Banglaore and an Asian edition,
printed and published from Singapore. The business-to-business
magazine tracks the growth of life science companies, captures the
emerging technological and entrepreneurial trends in the area of
Life Sciences which include pharmaceutical, biotechnology, medical
technology, bio-agriculture and bio-fuels. The combined readership
of both the editions of the magazine, which is available in
multiple formats as a fortnightly digital magazine, Web site, with
updated daily news and daily electronic newsletter, is over
200,000. The readership includes the region's top policy makers,
scientists, entrepreneurs, industry leaders, other influencers who
are part of the Life Sciences ecosystem. The Web sites of the two
editions have over 100,000 unique visitors. About S*BIO Pte Ltd
S*BIO is a privately-held biotech company focused on the research
and clinical development of novel targeted small molecule drugs for
the treatment of cancer with leading programs around histone
deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939,
entered the clinic in 2007. SB1518, S*BIO's potent and
orally-active JAK2 inhibitor, also entered the clinic in 2008 and
has received orphan drug designation from the U.S. FDA. S*BIO has
entered into a development collaboration, and option & license
agreement with Onyx Pharmaceuticals, Inc. to develop and
commercialize SB1518 and its other novel JAK2 inhibitor, SB1578.
S*BIO's SB1317, a novel multi-kinase inhibitor, is in pre-clinical
development and under a worldwide exclusive license with Tragara
Pharmaceuticals, Inc. for its development and commercialization. In
line with its vision to be a leading fully-integrated
oncology-focused biotech company in Asia Pacific, S*BIO has
established a state-of-the-art R&D infrastructure, complemented
by a strong clinical development team. S*BIO has strong links with
a network of medical oncologists in Asia Pacific and its investors
include EDB Investments' biomedical sciences subsidiary Bio*One
Capital, Aravis Ventures, Novartis Bioventures and other
international funds. More information about S*BIO can be found at
http://www.sbio.com/. S*BIO Pte Ltd: Russo Partners: Stephen Keith
Rhind, Ph.D. Tony Russo +1 212-845-4251 Senior Vice President,
Corporate Development Tel: +65 6827 5000 (Singapore) Andreas
Marathovouniotis +1 212-845-4235 DATASOURCE: S*BIO Pte Ltd CONTACT:
Stephen Keith Rhind, Ph.D., Senior Vice President, Corporate
Development, S*BIO Pte Ltd, +65-6827-5000 (Singapore), ; Tony
Russo, +1-212-845-4251, , or Andreas Marathovouniotis,
+1-212-845-4235, , both of Russo Partners, for S*BIO Pte Ltd Web
Site: http://www.sbio.com/
Copyright